OncoMed Pharma (OMED) Misses Q4 EPS by 23c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
OncoMed Pharmaceuticals Reports Full Year and Fourth Quarter 2014 Financial Results and Recent Highlights
March 12, 2015 4:02 PM EDTREDWOOD CITY, Calif., March 12, 2015 (GLOBE NEWSWIRE) -- OncoMed Pharmaceuticals, Inc. (Nasdaq: OMED), a clinical-stage company developing novel therapeutics that target cancer stem cells (CSCs), or tumor-initiating cells, today reported financial results for the year and quarter ended December 31, 2014. As of December 31, 2014, cash, cash equivalents and marketable securities totaled $232 million. In addition, OncoMed highlighted selected corporate milestones for its clinical-stage development programs.
"2014 was a year of great progress in R&D combined with prudent financial management," said Paul J. Hastings, Chairman and Chief Executive Officer. "We have advanced two anti-cancer stem cell antibodies, demcizumab and... More
OncoMed Pharmaceuticals Reports Full Year and Fourth Quarter 2014 Financial Results and Recent Highlights
March 12, 2015 4:02 PM EDTREDWOOD CITY, Calif., March 12, 2015 (GLOBE NEWSWIRE) -- OncoMed Pharmaceuticals, Inc. (Nasdaq: OMED), a clinical-stage company developing novel therapeutics that target cancer stem cells (CSCs), or tumor-initiating cells, today reported financial results for the year and quarter ended December 31, 2014. As of December 31, 2014, cash, cash equivalents and marketable securities totaled $232 million. In addition, OncoMed highlighted selected corporate milestones for its clinical-stage development programs.
"2014 was a year of great progress in R&D combined with prudent financial management," said Paul J. Hastings, Chairman and Chief Executive Officer. "We have advanced two anti-cancer stem cell antibodies, demcizumab and... More
